RBC Capital Maintains Outperform on Aramark, Raises Price Target to $70
RBC Capital analyst Karl Green maintains Aramark (NYSE:ARMK) with a Outperform and raises the price target from $60 to $70.
Read original at benzingaEconomy · News reference
Dow Falls Over 50 Points Ahead of Inflation Data: Fear Index Remains in ‘Greed’ Zone
Stocks closed mostly lower on Monday, with the Fear and Greed index remaining in Greed zone. Investors await earnings results and CPI report.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 7:44 AM
- Checked
- Aug 11, 2026, 7:44 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on Aramark, Raises Price Target to $74
Citigroup analyst Leo Carrington maintains Aramark (NYSE:ARMK) with a Buy and raises the price target from $70.5 to $74.
Read original at benzingaJP Morgan Maintains Overweight on Aramark, Raises Price Target to $70
JP Morgan analyst Andrew Steinerman maintains Aramark (NYSE:ARMK) with a Overweight and raises the price target from $55 to $70.
Read original at benzingaStifel Maintains Buy on Aramark, Raises Price Target to $70
Stifel analyst Shlomo Rosenbaum maintains Aramark (NYSE:ARMK) with a Buy and raises the price target from $54 to $70.
Read original at benzingaCardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know
Cardinal Health's CFO Aaron Alt sold 42,000 shares worth $9.9 million on August 18, reducing his direct holdings to 20,495 shares. The sale occurred after the stock surged 57% over the past year. Despite the insider sale, the company maintains strong guidance with fiscal 2027 EPS projected at $12.40-$12.60 (13-15% growth), planned capital expenditures of $700 million, and at least $1 billion in share repurchases expected.
Read original at the-motley-foolRBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276
RBC Capital analyst Ryan Halsted initiates coverage on Cardinal Health (NYSE:CAH) with a Outperform rating and announces Price Target of $276.
Read original at benzinga